Epidiolex significantly reduces drop seizure frequency in Lennox-Gastaut syndrome, and convulsive seizure frequency in Dravet syndrome according to the results of a multi-center, randomized, double-blind, placebo-controlled trial conducted by GW pharmaceutical.
GW said this in a Thursday announcement about presenting the results results from two completed Epidiolex Phase 3 trials, one in Lennox-Gastaut syndrome (LGS) and one in Dravet syndrome (DS).
New US unit name
For the first time, company-sponsored activities will be conducted under Greenwich Biosciences, Inc., GW’s new name for its operating unit in the United States.
“We are very excited to share these data from our Phase 3 programs with the epilepsy community. These presentations are the culmination of intensive effort by the GW in-house team and more than 50 participating sites over the past two years, and reflect the courage and commitment of patients and their families. We can now focus on the ultimate goal, which is to gain approval for Epidiolex and make this much-needed treatment available,” said Justin Gover, GW’s Chief Executive Officer. “We have also reached an ideal moment to introduce our new U.S. identity, Greenwich Biosciences, which will be the face of our company to patients and their families, clinicians, and the general public in the United States.”
Greenwich Biosciences (pronounced “gren-ich”), headquartered in Carlsbad, California, is incorporated in the United States and 100% owned by UK-based GW Pharmaceuticals plc. As the corporate parent, GW will remain the publicly-traded entity, be responsible for regulatory filings in the United States, and control the ongoing development and intellectual property associated with Epidiolex and the rest of the company’s cannabinoid pipeline.